<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>RNA metabolism &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/rna-metabolism/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 30 Oct 2025 11:25:04 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>RNA metabolism &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>N6-Methyladenosine Methylation Identified as a Promising Therapeutic Target for Acute Lung Injury</title>
		<link>https://bioengineer.org/n6-methyladenosine-methylation-identified-as-a-promising-therapeutic-target-for-acute-lung-injury/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 30 Oct 2025 11:24:32 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[acute lung injury]]></category>
		<category><![CDATA[epigenetic therapy]]></category>
		<category><![CDATA[m6A methylation]]></category>
		<category><![CDATA[pulmonary inflammation]]></category>
		<category><![CDATA[RNA metabolism]]></category>
		<guid isPermaLink="false">https://bioengineer.org/n6-methyladenosine-methylation-identified-as-a-promising-therapeutic-target-for-acute-lung-injury/</guid>

					<description><![CDATA[Acute Lung Injury (ALI) remains a formidable challenge in critical care medicine, marked by devastating inflammation of the lung parenchyma and persistent hypoxemia. As mortality rates remain high, unraveling the molecular drivers of this pathological condition is imperative for the development of effective therapies. Recent advances have spotlighted the epigenetic regulation of gene expression, particularly [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">288946</post-id>	</item>
	</channel>
</rss>
